Literature DB >> 20042563

New developments in the medical management of prostate cancer.

Manish Kohli1, Donald J Tindall.   

Abstract

Prostate cancer is a substantial public health burden and a leading cause of cancer-related morbidity and mortality in the United States despite the observation that annual prostate cancer-specific mortality rates have been declining during the previous decade. Although the reasons for this positive development are unclear, a combination of factors may have contributed. This update will review ongoing developments and summarize therapeutic advances in prostate cancer treatment on the basis of the current understanding of prostate cancer biology. Literature for this review was selected in 2009 by searching PubMed for the following keywords: prostatic neoplasms, castration, androgen receptor, hormonal, and chemotherapy. Emphasis is placed on published clinical studies in advanced prostate cancer therapeutics in the past 5 to 10 years. Also included in the review are novel hormonal agents targeting the androgen receptor currently in development for the treatment of advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20042563      PMCID: PMC2800284          DOI: 10.4065/mcp.2009.0442

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  82 in total

1.  Cumulative association of five genetic variants with prostate cancer.

Authors:  S Lilly Zheng; Jielin Sun; Fredrik Wiklund; Shelly Smith; Pär Stattin; Ge Li; Hans-Olov Adami; Fang-Chi Hsu; Yi Zhu; Katarina Bälter; A Karim Kader; Aubrey R Turner; Wennuan Liu; Eugene R Bleecker; Deborah A Meyers; David Duggan; John D Carpten; Bao-Li Chang; William B Isaacs; Jianfeng Xu; Henrik Grönberg
Journal:  N Engl J Med       Date:  2008-01-16       Impact factor: 91.245

Review 2.  Screening for breast cancer with mammography.

Authors:  P C Gøtzsche; M Nielsen
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 3.  Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.

Authors:  Jonathan W Simons; Natalie Sacks
Journal:  Urol Oncol       Date:  2006 Sep-Oct       Impact factor: 3.498

4.  Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.

Authors:  Julius Gudmundsson; Patrick Sulem; Andrei Manolescu; Laufey T Amundadottir; Daniel Gudbjartsson; Agnar Helgason; Thorunn Rafnar; Jon T Bergthorsson; Bjarni A Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Margret Jakobsdottir; Jianfeng Xu; Thorarinn Blondal; Jelena Kostic; Jielin Sun; Shyamali Ghosh; Simon N Stacey; Magali Mouy; Jona Saemundsdottir; Valgerdur M Backman; Kristleifur Kristjansson; Alejandro Tres; Alan W Partin; Marjo T Albers-Akkers; Javier Godino-Ivan Marcos; Patrick C Walsh; Dorine W Swinkels; Sebastian Navarrete; Sarah D Isaacs; Katja K Aben; Theresa Graif; John Cashy; Manuel Ruiz-Echarri; Kathleen E Wiley; Brian K Suarez; J Alfred Witjes; Mike Frigge; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jose I Mayordomo; Lambertus A Kiemeney; William B Isaacs; William J Catalona; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2007-04-01       Impact factor: 38.330

5.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Authors:  Nancy L Keating; A James O'Malley; Matthew R Smith
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

6.  Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

Authors:  Tomasz M Beer; Christopher W Ryan; Peter M Venner; Daniel P Petrylak; Gurkamal S Chatta; J Dean Ruether; Charles H Redfern; Louis Fehrenbacher; Mansoor N Saleh; David M Waterhouse; Michael A Carducci; Daniel Vicario; Robert Dreicer; Celestia S Higano; Frederick R Ahmann; Kim N Chi; W David Henner; Alan Arroyo; Fong W Clow
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

7.  Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Authors:  Christopher S Saigal; John L Gore; Tracey L Krupski; Janet Hanley; Matthias Schonlau; Mark S Litwin
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

8.  A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.

Authors:  Eric J Small; N Simon Tchekmedyian; Brian I Rini; Lawrence Fong; Israel Lowy; James P Allison
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

9.  Preclinical antitumor activity of the oral platinum analog satraplatin.

Authors:  Katja Wosikowski; Lou Lamphere; Gerhard Unteregger; Volker Jung; Faith Kaplan; Jimmy P Xu; Benno Rattel; Maureen Caligiuri
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-31       Impact factor: 3.333

10.  A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

Authors:  Michael A Carducci; Fred Saad; Per-Anders Abrahamsson; David P Dearnaley; Claude C Schulman; Scott A North; Darryl J Sleep; Jeffrey D Isaacson; Joel B Nelson
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

View more
  35 in total

1.  Methanolic Fractions of Ornithogalum cuspidatum Induce Apoptosis in PC-3 Prostate Cancer Cell Line and WEHI-164 Fibrosarcoma Cancer Cell Line.

Authors:  Hamed Asadi; Mona Orangi; Dariush Shanehbandi; Zohreh Babaloo; Abbas Delazar; Leila Mohammadnejad; Fatemeh Zare Shahneh; Samira Valiyari; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2014-08-25

2.  Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.

Authors:  Arnaldo A Arbini; Margherita Greco; Jorge L Yao; Patricia Bourne; Ersilia Marra; Jer-Tsong Hsieh; Paul A di Sant'agnese; Loredana Moro
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

3.  Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal.

Authors:  Sanaz Memarzadeh; Houjian Cai; Deanna M Janzen; Li Xin; Rita Lukacs; Mireille Riedinger; Yang Zong; Karel DeGendt; Guido Verhoeven; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

4.  Refurbishing Mayo Clinic Proceedings: 2011-2012.

Authors:  William L Lanier
Journal:  Mayo Clin Proc       Date:  2011-01       Impact factor: 7.616

5.  [Citron Rho-interacting serine/threonine kinase knockdown suppresses prostate cancer cell proliferation and metastasis by blocking Hippo-YAP pathway].

Authors:  Chen Haiping; Xiang Qi; Liu Dawei; Wei Qiang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-03-30

6.  The high cost of cancer drugs and what we can do about it.

Authors:  Mustaqeem Siddiqui; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

7.  Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men.

Authors:  Graham Scott; Irfan Ahmad; Katy Howard; David MacLean; Cristina Oliva; Steve Warrington; Darren Wilbraham; Paul Worthington
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 8.  Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Authors:  Rachel S Kelly; Matthew G Vander Heiden; Edward Giovannucci; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-06       Impact factor: 4.254

9.  Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Lorie A Ellis; Marie-Hélène Lafeuille; Laurence Gozalo; Dominic Pilon; Patrick Lefebvre; Scott McKenzie
Journal:  Am Health Drug Benefits       Date:  2015-06

10.  Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.

Authors:  Marie-Hélène Lafeuille; Jonathan Gravel; Amanda Grittner; Patrick Lefebvre; Lorie Ellis; R Scott McKenzie
Journal:  Am Health Drug Benefits       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.